{"nct_id":"NCT05216432","title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2021-12-08","start_date_type":"ACTUAL","primary_completion_date":"2027-04-30","primary_completion_date_type":"ESTIMATED","completion_date":"2027-04-30","completion_date_type":"ESTIMATED","phases":["PHASE1"],"tickers":["RLAY"]}